How GLP-1 Receptor Agonists Relate to Body Clock, Sleep, and Metabolic Disease

Intestinal L-cells possess an intrinsic circadian clock that governs rhythmic GLP-1 secretion. Under physiological conditions, circulating GLP-1 exhibits clear diurnal variation. In rodents, secretion peaks near the onset of the feeding period and reaches a nadir during the fasting or rest phase [38]. Human studies mirror this pattern, with identical nutrient loads eliciting significantly greater GLP-1 and GIP release in the morning than in the afternoon [9]. In one study, early GLP-1 area under the curve (AUC₃₀) was nearly twofold higher in the morning compared with the afternoon (300 ± 40 vs. 160 ± 30 pmol/L·30 min, p = 0.002) [9].

Mechanistic studies have confirmed that this rhythmicity depends on intact molecular clock machinery. In vivo, GLP-1 secretion parallels oscillations in the core clock gene Bmal1 (Arntl) within L-cells [39]. Targeted deletion or knockdown of Bmal1 in L-cells abolishes normal circadian variation in GLP-1 release, resulting in blunted secretion at the expected peak [13]. In Gcg-Arntl knockout mice, the rhythmic GLP-1 surge is lost, and peak GLP-1 levels are significantly reduced (p < 0.05), with downstream consequences including impaired timing of insulin secretion and disruption of intestinal homeostasis [12].

The circadian clock within intestinal L-cells governs time-of-day variation in GLP-1 secretion by directly regulating the exocytotic machinery required for hormone release. The core clock protein BMAL1 binds to promoter regions of genes encoding secretagogin (SCGN) and syntaxin-binding protein-1 (STXBP1)—SNARE-associated proteins that facilitate vesicle fusion with the cell membrane [40]. Knockdown of either Scgn or Stxbp1 selectively impairs GLP-1 secretion at peak times while leaving baseline secretion unaffected (p < 0.01 and p < 0.05, respectively) [40]. In vivo, genetic deletion of Scgn using three independent knockout models abolishes the normal diurnal rhythm of GLP-1 secretion in response to oral glucose, with RNA-Seq revealing disrupted vesicle transport and synaptic protein interaction pathways [41]. These findings demonstrate that the molecular clock primes L-cells for optimal nutrient responsiveness at specific times of day through transcriptional control of secretory machinery.

Translational interpretation of these findings requires caution. Most mechanistic data derive from nocturnal rodent models, in which feeding, activity, and melatonin secretion are phase-inverted relative to diurnal humans. While the presence of circadian incretin regulation appears conserved, the temporal alignment of GLP-1 peaks and metabolic activity cannot be directly extrapolated from murine models to human physiology.

Beyond exocytotic control, the circadian clock also determines whether L-cells have sufficient metabolic capacity to secrete GLP-1. A central mechanism involves BMAL1-dependent regulation of nicotinamide adenine dinucleotide (NAD⁺) biosynthesis through nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD⁺ salvage pathway [42,43]. In intact systems, Nampt expression and NAD⁺ availability oscillate with circadian timing, supporting time-of-day–dependent GLP-1 secretion. Disruption of this axis has clear functional consequences: suppression of Bmal1 or pharmacologic inhibition of NAMPT reduces NAD⁺ levels, impairs mitochondrial energy production, and blunts GLP-1 release [44]. Intestinal Nampt knockout mice develop reduced GLP-1 secretion, impaired early-phase insulin responses, and postprandial hyperglycemia, a phenotype reversible with NAD⁺ repletion using nicotinamide mononucleotide (NMN) [43]. Similar defects in intestinal NAD⁺ metabolism are observed in diet-induced obesity, paralleling impaired incretin secretion. Collectively, these findings support a clinically relevant BMAL1–NAMPT–NAD⁺ pathway linking circadian alignment to incretin competence, with implications for metabolic vulnerability in obesity, aging, and circadian disruption [42,45].

The circadian GLP-1 axis appears particularly sensitive to dietary stress, especially exposure to saturated fatty acids common in Western diets. In rodent models, high-fat or high-sucrose feeding abolishes the normal diurnal rhythm of GLP-1 secretion, resulting in similar hormone levels at times when peak–trough differences would normally be expected [46]. Mechanistic studies suggest that palmitate, a dominant dietary saturated fatty acid, directly disrupts L-cell clock function by suppressing Bmal1 expression, reducing downstream Nampt-mediated NAD⁺ availability, and impairing mitochondrial ATP production required for hormone release (p < 0.05–0.001) [1,44]. Notably, palmitate fails to further suppress GLP-1 secretion in Bmal1-deficient L-cells, indicating that its primary target is the molecular clock rather than the secretory machinery itself [47]. Supporting this model, parallel work in hepatocytes shows that palmitate destabilizes BMAL1–CLOCK interactions via inhibition of SIRT1, a mechanism likely shared by intestinal L-cells [48]. With sustained exposure, palmitate also promotes ceramide-mediated apoptosis of GLP-1–producing cells, contributing to reduced L-cell mass in high-fat feeding states [49]. Collectively, these findings link dietary lipotoxicity to incretin dysfunction in obesity and suggest that obesogenic diets impair GLP-1 signaling not only through excess caloric load but by directly disrupting the circadian architecture that governs hormone release.

Preclinical knockout models provide important biological support for the clinical relevance of circadian regulation of GLP-1 secretion. In addition to L-cell–specific Bmal1 deletion, which directly establishes the requirement of BMAL1 for rhythmic GLP-1 release, mice lacking other core clock components (including Clock and Period genes) exhibit disrupted feeding behavior, impaired glucose homeostasis, and abnormal daily patterns of incretin secretion [13,19,50,51]. Although interpretation of germline Bmal1 knockout models is limited by global circadian disruption, the consistency of these findings across systems supports the concept that circadian control of GLP-1 is physiologically necessary [19,50,51]. L-cell clock disruption appears to extend beyond hormone secretion alone. Inducible L-cell Bmal1 knockout models demonstrate alterations in intestinal immune balance, gut microbial composition, and metabolite profiles, suggesting that rhythmic GLP-1 signaling may contribute to maintaining intestinal homeostasis [13]. From a clinical perspective, these data reinforce the idea that circadian misalignment and dietary disruption may impair GLP-1 biology at multiple levels, with downstream consequences for metabolic and gastrointestinal health. A conceptual overview of circadian regulation of GLP-1 secretion and its bidirectional interaction with central and peripheral clocks, as shown in Figure 1.

Circadian misalignment, whether from shift work, jet lag, or irregular light exposure, disrupts the normal 24 h pattern of GLP-1 secretion. Human studies confirm these findings. In healthy male volunteers, Gil-Lozano and colleagues demonstrated that identical meals elicited significantly greater GLP-1 responses when consumed at 11:00 a.m. compared with 11:00 p.m., establishing a clear diurnal pattern in human L-cell activity [1]. Critically, sleep deprivation combined with nocturnal light exposure induced profound derangements in GLP-1 and insulin responses, abrogating the normal time-of-day variation in incretin secretion [1]. These alterations were not observed in sleep-deprived participants maintained under dark conditions, indicating a direct effect of light rather than sleep loss alone on glucoregulatory pathways [3]. Phase-delayed circadian misalignment in controlled laboratory settings similarly decreases GLP-1 concentrations (p = 0.02) while increasing glucose levels, demonstrating that even modest shifts in circadian timing impair incretin-glucose coordination [52]. Metabolic regulation is influenced not only by the timing of light exposure but also by the 24 h amplitude of light. Robust daytime natural light strengthens circadian entrainment and metabolic oscillation amplitude, whereas diminished daytime exposure combined with artificial evening light can flatten circadian rhythms [53]. This reduced light amplitude, common in modern indoor lifestyles, may independently impair glucose and lipid homeostasis and could potentially blunt endogenous incretin rhythmicity [54,55].

These findings carry direct clinical relevance. Shift workers experience chronic exposure to light at night, suppressed melatonin rhythms, and mistimed feeding all factors that disrupt the circadian GLP-1 axis [6,56]. The resulting “scrambled” incretin profile, characterized by blunted morning GLP-1 responses and delayed postprandial peaks, mirrors the metabolic phenotype observed in epidemiological studies linking shift work to a 20–35% increased risk of type 2 diabetes. Long-term sleep deprivation in primate models similarly induces insulin resistance associated with impaired GLP-1 signaling, effects that can be partially attenuated by probiotic supplementation targeting the gut microbiome [57]. Collectively, these data suggest that circadian disruption represents a modifiable pathway through which modern lifestyle factors such as irregular light exposure, curtailed sleep, and mistimed eating contribute to incretin dysfunction and metabolic disease risk.

We now recognize the gut microbiome as essential for circadian GLP-1 secretion. Microbiome depletion in germ-free or antibiotic-treated mice completely abolishes the postprandial GLP-1 response, an effect restored by fecal microbiota transplantation [2,58]. Specific taxa, including Ruminococcaceae and Lachnospiraceae oscillate diurnally alongside intestinal clock gene expression, and this coordination is disrupted in type 2 diabetic models with impaired GLP-1 sensitivity [7]. Mechanistically, gut bacteria regulate GLP-1 through multiple pathways: Akkermansia muciniphila secretes a protein (P9) that induces GLP-1 release via ICAM-2 interaction in an IL-6–dependent manner, while microbial bile acid metabolism, particularly ω-muricholic acid and hyocholic acid, stimulates L-cells through TGR5 signaling [59,60]. Short-chain fatty acids (SCFA) from bacterial fermentation bind free fatty acid receptors 2 and 3 on L-cells to promote GLP-1 secretion, though the nuclear receptor FXR can inhibit this pathway by reducing FFAR2 expression [61,62]. In humans, circulating short-chain fatty acid (SCFA) concentrations are typically in the low micromolar range (e.g., acetate ≈ 20–80 µmol/L, propionate ≈ 1–13 µmol/L, butyrate ≈ 0.5–5 µmol/L in fasting plasma) have been positively associated with fasting GLP-1 levels in observational cohorts, suggesting that microbial metabolites reaching the systemic circulation may be more directly linked to incretin function than fecal concentrations alone [63]. These findings suggest that a eubiotic microbiome supports robust circadian GLP-1 secretion, whereas dysbiosis, as occurs in obesity and type 2 diabetes, may dampen or desynchronize incretin rhythms, opening opportunities for prebiotic, probiotic, or synbiotic co-treatment strategies to enhance GLP-1-based therapies [11].

Beyond light, sleep, and the microbiome, we recognize several additional modulators of circadian GLP-1 secretion with clinical relevance. Meal timing exerts powerful effects: time-restricted feeding promotes GLP-1 secretion and regulates appetite through enhanced Lactobacillus colonization and tryptophan-derived indole-3-lactic acid production, which increases enteroendocrine cell differentiation [64]. Conversely, erratic meal patterns and obesogenic diets render GLP-1 secretion arrhythmic, eliminating the normal peak–trough differences essential for coordinated metabolic responses [2]. Glucocorticoids represent another critical modulator: dexamethasone suppresses GLP-1 secretion both in vitro and in vivo through glucocorticoid receptor activation in L-cells, reducing proglucagon expression at the transcriptional level via a receptor dimerization-dependent mechanism [65]. This bidirectional relationship is notable because GLP-1 itself activates the hypothalamic–pituitary–adrenal (HPA) axis, increasing circulating cortisol in humans and corticosterone in rodents. These effects are observed with both endogenous GLP-1 and therapeutic GLP-1 receptor agonists [65]. Chronic stress and elevated glucocorticoids may therefore blur GLP-1 rhythmicity through both direct L-cell suppression and central feedback mechanisms, potentially contributing to the metabolic dysregulation observed in stress-related disorders.

In summary, we recognize that circadian misalignment arising from abnormal light exposure, sleep loss, shift work, or microbiome disruption impairs the coordinated timing of GLP-1 secretion required for metabolic homeostasis. These findings suggest that clinical strategies and trial designs should move beyond dose-centric approaches and begin to account for when GLP-1 signaling is engaged, including attention to dosing time, sleep–wake patterns, and circadian context, as part of precision metabolic therapy.

Beyond its peripheral actions, we recognize GLP-1 as an important neuropeptide linking feeding behavior to central circadian control. GLP-1–producing preproglucagon (PPG) neurons in the caudal nucleus tractus solitarius (NTS) project extensively to hypothalamic regions involved in both appetite and circadian regulation, including the paraventricular nucleus (PVN), arcuate nucleus (ARC), and dorsomedial hypothalamus (DMH) [66,67,68]. The DMH serves as a key relay between feeding-related signals and the master clock in the suprachiasmatic nucleus (SCN). Experimental disruption of GLP-1 receptor signaling in the DMH leads to loss of normal diurnal feeding patterns, hyperphagia, weight gain, and blunted circadian metabolic rhythms [69]. GLP-1 signaling in this pathway appears necessary for conveying meal timing information to the SCN. Together, these data position central GLP-1 signaling as a critical mechanism by which feeding schedules help entrain circadian rhythms of behavior and metabolism [67].

In addition to being regulated by circadian clocks, we find that GLP-1 signaling can itself influence clock timing in peripheral tissues. Preclinical studies show that GLP-1 receptor agonists modulate peripheral clock gene expression through mechanisms distinct from refeeding; for example, exendin-4 alters hepatic Per1 mRNA expression and modifies feeding-induced clock gene changes in the liver and adipose tissue [70]. These effects are strongly time-dependent: exenatide administered at the beginning of the active period (ZT 12) counteracts mistimed feeding–induced phase shifts in the hepatic clock, whereas dosing at the rest period onset (ZT 0) exacerbates circadian disruption [71]. Importantly, these clock-modulating effects are largely lost in mice with central nervous system–specific GLP-1 receptor knockdown, indicating that peripheral clock resetting occurs indirectly through brain-mediated pathways rather than direct hepatic action [71]. Beyond the liver, GLP-1 mimetics such as liraglutide and exenatide induce high-amplitude rhythmic PER2 expression in pancreatic β-cells via adenylate cyclase–dependent signaling, highlighting cell-specific clock modulation [72]. From a translational perspective, these findings suggest that GLP-1RA dosing time may be clinically relevant, particularly in patients with irregular eating patterns or circadian disruption, providing a biological rationale for GLP-1–based chronotherapy.

In summary, we recognize that GLP-1 functions not only as a gut-derived incretin but also as a neuromodulator linking metabolic signals to central circadian control. Through GLP-1 receptors in the dorsomedial hypothalamus and related hypothalamic nuclei, incretin signaling helps align feeding behavior with the master clock, as disruption of this pathway abolishes normal diurnal feeding patterns and blunts meal-induced activation of the suprachiasmatic nucleus [69,73]. Beyond the brain, timed activation of GLP-1 receptor pathways can modify peripheral clock timing: exenatide administered during the active phase attenuates mistimed feeding–induced phase shifts in the liver, whereas dosing during the rest phase exacerbates circadian disruption via centrally mediated mechanisms [70,71]. In pancreatic islets, GLP-1 mimetics such as liraglutide and exenatide also induce robust, rhythmic PER2 expression in β-cells, demonstrating cell-specific clock synchronization [72]. Taken together, these central and peripheral actions position GLP-1 receptor agonists as potential tools for addressing circadian disruption. We next compare semaglutide, liraglutide, and tirzepatide with respect to how they may differentially engage these chronometabolic pathways, including effects on sleep.

GLP-1 receptor agonists differ meaningfully in pharmacokinetics, central engagement, and downstream effects on feeding behavior, with potential implications for chronometabolic regulation [74]. Liraglutide, with a half-life of 11–15 h, produces daily peaks and troughs and is more amenable to time-of-day tailoring, whereas semaglutide (half-life ~165–168 h) and tirzepatide (half-life ~117 h) provide near-continuous receptor engagement across the 24 h cycle with once-weekly dosing [75,76]. This sustained exposure may blunt late-day hunger and reduce nocturnal eating, reinforcing circadian-aligned feeding patterns; both agents reduce food cravings and binge eating, with semaglutide lowering binge-eating prevalence and liraglutide improving eating-disorder risk scores versus placebo [77].

Evidence on receptor desensitization is reassuring but nuanced. Although chronic GLP-1RA exposure induces homologous receptor desensitization in vitro, GLP-1R–dependent glucose homeostasis appears preserved in vivo [78]. A human pilot study likewise showed no tolerance to liraglutide’s glucose-lowering effect over 21 days [79]. Mechanistically, GLP-1 receptors are functionally Gs-selective and recycle between membrane microdomains rather than undergoing classical β-arrestin–mediated desensitization, which may explain the durability of long-acting agents [74,80]. Nonetheless, tolerance develops for some effects such as gastric motility, and one murine study reported loss of glucose-lowering efficacy after 18 days, underscoring potential species- or dose-dependent differences [77].

The metabolic effects of GLP-1 receptor agonists extend beyond weight loss. In a randomized controlled trial, Mashayekhi et al. showed that liraglutide improved insulin sensitivity by HOMA-IR, HOMA2, and the Matsuda index—within two weeks, before meaningful weight reduction occurred [81]. These effects were GLP-1 receptor–dependent, as they were reversed by exendin [9,39]. In contrast, diet-induced weight loss of similar magnitude improved HOMA-based indices but not the Matsuda index or fasting glucose, suggesting that GLP-1 receptor agonists engage pathways beyond simple caloric restriction [81,82].

Clinically, this early, weight-independent insulin sensitization suggests that GLP-1 therapy may begin restoring metabolic alignment before significant weight loss, potentially strengthening the reciprocal relationship between glucose control, sleep, and circadian stability.

All three agents, namely liraglutide, semaglutide, and tirzepatide acts on GLP-1 receptors accessible from the periphery, particularly within brainstem regions such as the area postrema and nucleus tractus solitarius, which lie outside a fully intact blood–brain barrier and are central to appetite regulation and nausea [83,84]. Experimental data indicate that the nucleus tractus solitarius is a key site of action, as selective GLP-1 receptor knockdown in this region attenuates the anorectic and weight-reducing effects of liraglutide [83,84].

Liraglutide also gains access to hypothalamic feeding centers via tanycyte-mediated transport rather than classical blood–brain barrier penetration. Disruption of this pathway abolishes hypothalamic neuronal activation and the drug’s effects on food intake and body weight [85]. Within the arcuate nucleus, liraglutide activates anorexigenic POMC/CART neurons and suppresses orexigenic NPY/AgRP signaling, providing a neural basis for its weight-loss efficacy [86]. GLP-1 receptors are present in the human hypothalamus and brainstem, and liraglutide alters central responses to highly palatable food cues in individuals with diabetes [87].

Semaglutide appears to engage similar central pathways, with preferential hypothalamic accumulation, although available data suggest that acylated GLP-1 analogs act primarily through circumventricular access and specialized transport rather than direct blood–brain barrier penetration [74,88]. Its longer half-life likely enables more sustained central receptor engagement.

In contrast, tirzepatide’s central nervous system penetration is less well characterized, and much of its additional efficacy is thought to derive from peripheral mechanisms and dual GLP-1/GIP receptor signaling [89]. The extent to which tirzepatide directly crosses the intact blood–brain barrier remains uncertain, and any central effects may reflect limited penetration, signaling at circumventricular organs, or indirect modulation through peripheral vagal pathways. While GIP receptors are expressed in the brain, whether tirzepatide engages them centrally at physiological concentrations and with what relevance to circadian or behavioral regulation remains uncertain [89]. Definitive pharmacokinetic studies quantifying CNS exposure in humans are lacking.

GLP-1 receptor agonists produce sustained reductions in appetite and caloric intake through central satiety pathways and improved control of eating behavior [78,90,91]. In clinical trials, semaglutide 2.4 mg significantly improved craving control across multiple food domains, with reductions in craving scores correlating with weight loss over long-term follow-up [92]. Oral semaglutide 50 mg reduced ad libitum energy intake by nearly 40% at 20 weeks, alongside lower hunger and food cravings [93]. Tirzepatide similarly reduced energy intake early in treatment and was associated with marked decreases in appetite, food cravings, and overeating tendencies [94]. In head-to-head comparisons, tirzepatide and semaglutide both reduced appetite versus placebo, with comparable effects on energy intake despite greater weight loss with tirzepatide [95].

With respect to eating timing, direct evidence that GLP-1RAs specifically reduce late-night or nocturnal eating remains limited. Semaglutide has been shown to markedly reduce emotional eating and craving prevalence, suggesting broad improvement in maladaptive eating behaviors rather than targeted effects on meal timing [96]. From a circadian nutrition perspective, the sustained appetite suppression of long-acting agents may indirectly favor earlier caloric intake during periods of higher insulin sensitivity, although this remains hypothesis-generating and requires prospective, time-stamped dietary studies. Liraglutide’s shorter half-life (~13 h) raises the theoretical possibility of time-of-day tailoring, but current clinical guidance supports consistent daily dosing rather than circadian-directed administration [75,97].

From a clinical standpoint, the most consistent sleep-related benefit of GLP-1 receptor agonists is improvement in obstructive sleep apnea (OSA). However, it is essential to recognize that this benefit is largely, if not entirely, mediated through weight loss rather than direct pharmacologic action on sleep physiology. Weight reduction decreases pharyngeal fat deposition, reduces mechanical load on the upper airway, and improves respiratory mechanics, which are effects that would be expected with any intervention producing comparable weight loss. Whether GLP-1RAs exert any weight-independent effects on OSA severity remains unestablished. Given the high burden of OSA in obesity and type 2 diabetes, this represents a clinically meaningful downstream effect of incretin-based therapy. In the SCALE Sleep Apnea trial, liraglutide 3.0 mg produced a significantly greater reduction in apnea–hypopnea index (AHI) than placebo over 32 weeks, with improvements closely linked to weight reduction [98]. Tirzepatide appears to confer the largest OSA benefit to date: in the SURMOUNT-OSA trials, tirzepatide reduced AHI by approximately 20–24 events per hour versus placebo, both in patients using positive airway pressure therapy and those not receiving PAP [14]. These improvements were accompanied by reduced hypoxic burden, lower inflammatory markers, and better patient-reported sleep outcomes. A recent meta-analysis of randomized trials further supports a class effect, demonstrating a mean AHI reduction of 11.6 events per hour with incretin-based therapies compared with usual care [75].

Beyond OSA, direct effects of GLP-1 receptor agonists on human sleep architecture remain poorly defined. While preclinical studies suggest potential sleep-promoting effects, human data are limited, and reported improvements in subjective sleep quality likely reflect weight loss and OSA improvement rather than primary neuromodulatory actions [99]. Sleep-related adverse effects, including insomnia or fragmented sleep, are uncommon and usually related to gastrointestinal symptoms. At present, available clinical evidence does not support intentional use of GLP-1 receptor agonists to directly modify sleep architecture or circadian sleep timing independent of their metabolic effects. Table 1 summarizes agent-specific pharmacokinetic, central, circadian, and sleep-related considerations for commonly used GLP-1 receptor agonists

In current clinical practice, we can already apply several actionable strategies when initiating GLP-1 receptor agonist therapy. First, we should assess patient schedules. Asking about work hours, meal timing, and sleep habits helps contextualize dosing recommendations, particularly for patients with nontraditional schedules such as shift work, even though formal evidence for circadian-directed dosing remains limited.

Second, we should monitor tolerability in relation to the time of day. Common gastrointestinal adverse effects such as nausea, vomiting, diarrhea, and constipation typically occur during dose escalation. When symptoms arise, it is reasonable to assess whether they cluster around dosing time and consider timing adjustments alongside standard mitigation strategies such as slower up-titration, smaller meals, avoidance of high-fat foods, and adequate hydration [112,113]. However, the temporal dynamics of these adverse effects remain under-characterized. Whether these symptoms exhibit circadian clustering in relation to gastric emptying rhythms or postprandial hormonal peaks is unknown. Understanding the chronobiology of adverse effects may provide an opportunity to optimize dosing time to improve adherence without compromising efficacy.

Third, we should emphasize routine. Consistent daily or weekly dosing, coupled with regular meal timing and sleep schedules, aligns with current guidance and may synergize with metabolic effects. Anchoring medication administration to stable habits such as a morning routine or regular breakfast can also support adherence and circadian regularity.

Fourth, we should actively leverage weight loss to improve sleep. As patients lose weight, we should reassess symptoms of obstructive sleep apnea and overall sleep quality. Many patients experience reduced snoring and improved daytime alertness, and some may be able to down-titrate or discontinue PAP (Positive Airway Pressure) therapy under supervision. Persistent fatigue despite weight loss should prompt evaluation for residual or alternative sleep disorders.

Finally, incorporating simple sleep and circadian assessments into metabolic care may improve outcomes. Brief tools such as STOP-BANG or the Pittsburgh Sleep Quality Index can identify patients who warrant further evaluation. Emerging data also suggest that adequate sleep duration may amplify glycemic benefits of GLP-1 receptor signaling, with gene–environment studies showing interactions between GLP-1 receptor variants and sleep duration on HbA1c [53]. Addressing sleep regularity alongside GLP-1RA therapy may therefore enhance durability of response and long-term adherence.

This review has several limitations. This review is narrative in structure and does not employ a formal systematic search strategy, predefined inclusion/exclusion criteria, or quantitative meta-analysis. As such, it may be subject to selection bias, and the magnitude of effect sizes across heterogeneous studies cannot be formally compared. The intent of this work is hypothesis-generating and integrative rather than quantitatively definitive. Additionally, much of the mechanistic evidence derives from preclinical models, and translational applicability to humans remains uncertain. Clinical data directly evaluating time-of-day administration of GLP-1 receptor agonists are limited, and most available studies were not designed as chronopharmacological trials. Also to note, associations between GLP-1 signaling, sleep disorders, and microbiome alterations are largely observational, precluding causal inference. Existing clinical trials have employed fixed dosing schedules, leaving the chronotherapeutic hypothesis largely speculative. No randomized controlled trials have directly compared different times of day for GLP-1RA administration or stratified outcomes by patient chronotype or circadian phase markers. Furthermore, much of the mechanistic foundation derives from nocturnal animal models, limiting direct chronological translation to human clinical practice. Finally, heterogeneity in study populations, endpoints, and dosing regimens limits cross-study comparability.

Finally, we see several clinically relevant directions for future work at the intersection of circadian biology and GLP-1 receptor agonist therapy. A key unanswered question is whether GLP-1 receptor agonists meaningfully influence circadian clock function in humans, as suggested by preclinical studies showing time-dependent effects on peripheral clock gene expression. Determining whether such effects occur in human tissues and whether they translate into better metabolic control would directly inform clinical use.

From a practical standpoint, combining GLP-1 receptor agonists with circadian-targeted interventions warrants careful study. Strategies such as melatonin supplementation or timed light exposure can improve circadian alignment and sleep quality in selected populations, including shift workers, but their metabolic effects are variable and context dependent. Whether pairing these approaches with GLP-1RA therapy improves glycemic or weight outcomes remains unknown and should be tested in well-designed clinical trials. Critically, future trials should move beyond simple morning-versus-evening comparisons to test truly personalized chronotherapy, for example, matching GLP-1RA administration to individual circadian phenotypes assessed via chronotype questionnaires, actigraphy, or circadian biomarkers such as dim-light melatonin onset.

We also need trials that reflect real-world circadian diversity. Current outcome studies have not examined whether responses to GLP-1 receptor agonists differ by chronotype, shift-work status, or circadian phase markers. Incorporating tools already familiar to clinicians—such as actigraphy and time-stamped continuous glucose monitoring could help identify patients who benefit most from timing-informed therapy.

No new data were created or analyzed in this study. Data sharing is not applicable to this article.